Clinical Trials Logo
  1. Home
  2. Transthyretin Amyloidosis
  3. NCT03759379

HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)

Transthyretin Amyloidosis Clinical Trial

Official title:
HELIOS-A: A Phase 3 Global, Randomized, Open-label Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of vutrisiran (ALN-TTRSC02) in participants with hereditary transthyretin amyloidosis (hATTR amyloidosis). Participants will receive vutrisiran subcutaneous (SC) injection once every 3 months (q3M) or the reference comparator patisiran intravenous (IV) injection once every 3 weeks (q3w) during the 18 month Treatment Period. This study will use the placebo arm of the APOLLO study (NCT01960348) as an external comparator for the primary and most other efficacy endpoints during the 18 Month Treatment Period. Following the 18 Month Treatment Period, all participants will be randomized to receive vutrisiran SC injection once every 6 months (q6M) or q3M in the Randomized Treatment Extension (RTE) Period.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03759379
Study type Interventional
Source Alnylam Pharmaceuticals
Contact
Status Active, not recruiting
Phase Phase 3
Start date February 14, 2019
Completion date October 2026
View Details
See also
  Status Clinical Trial Phase
Completed NCT03190577 - Assessment of the Prevalence of TTR Amyloid Neuropathy in a Population of Patients With Neuropathy of Unknown Aetiology N/A
Completed NCT03588468 - Expanding the Biomarkers in Familial Amyloid Neuropathy: MRI and Motor Unit Estimation by Electrophysiological Study N/A
Completed NCT03591757 - Short-term Effects of TOLCAPONE on Transthyretin Stability in Subjects With Leptomeningeal TTR Amyloidosis (ATTR) Early Phase 1
Completed NCT05075798 - Study of Cerebral MRI Anomalies in Mutated Transthyretin Amyloidosis Patients
Recruiting NCT05577819 - Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF N/A
Terminated NCT04611204 - Transthyretin Cardiac Amyloidosis in Patients With Idiopathic Carpal Tunnel Syndrome Referred for Release Surgery
Completed NCT03352089 - Positron Emission Tomography / Magnetic Resonance Imaging in Aortic Stenosis
Recruiting NCT05814380 - The Regional Scintigraphic DPD Uptake in Cardiac Transthyretin Amyloidosis.
Completed NCT03886155 - Cardiac Amyloidosis Screening at Trigger Finger Release
Completed NCT03923920 - Screening for Systemic Amyloidosis Via the Ligamentum Flavum
Completed NCT03862807 - Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver Transplant Phase 3
Completed NCT02792790 - Carpal Tunnel Syndrome and Amyloid Cardiomyopathy
Completed NCT03860935 - Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy Phase 3
Not yet recruiting NCT06465810 - Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
Recruiting NCT04963985 - The Effect of Tafamidis on Transthyretin Stabilization, Safety, Tolerability and Efficacy in Transthyretin Amyloid Polyneuropathy Patients Phase 4
Recruiting NCT05409833 - Systemic Transthyretin Amyloidosis: Carpal Tunnel Syndrome in a Portuguese Population
Recruiting NCT05635045 - Evuzamitide in PET/CT to Measure Potential Therapeutic Response in ATTR Phase 2
Completed NCT01171859 - Safety, Efficacy and Pharmacokinetics of Doxycycline Plus Tauroursodeoxycholic Acid in Transthyretin Amyloidosis Phase 2
Recruiting NCT03237494 - TRAMmoniTTR Study Genetic Screening of an At-risk Population for hATTR and Monitoring of TTR Positive Subjects
Recruiting NCT04899180 - Prevalence of Transthyretin Cardiac Amyloidosis in Clinically Significant Aortic Stenosis Early Phase 1